2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1718 Nuclear factor I Χ (NFIX) mutations in acute myeloid leukemia with DEK::NUP214 fusion

Lisa Latzko, Simona Di Gaetano2, Vanessa Cristina Arfelli, PhD3, Maria Solovey, PhD4, Tobias Herold, MD5, Katrin Schranz6, Stephanie Schneider7, Annika Dufour, PhD, MSc8, Maja Rothenberg-Thurley9, Karsten Spiekermann, MD10, Kristian Unger11, Christian Kellner12, Christian Wichmann13, Sebastian Vosberg, PhD14, Philipp A. Greif, MD15
1 Experimental Leukemia and Lymphoma Research, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany, German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany
2 Experimental Leukemia and Lymphoma Research, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München, Germany
3 Experimental Leukemia and Lymphoma Research, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany, German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany
4 Experimental Leukemia and Lymphoma Research, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München, Germany
5 Department of Hematology, Oncology, and Stem-Cell Transplantation, Munich Hospital Bogenhausen, Munich Municipal Hospital Group, Munich, Germany, Laboratory for Leukemia Diagnostics, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
6 Experimental Leukemia and Lymphoma Research, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany, German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany
7 Laboratory for Leukemia Diagnostics, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
8 Laboratory for Leukemia Diagnostics, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
9 Laboratory for Leukemia Diagnostics, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
10 Experimental Leukemia and Lymphoma Research, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany, German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany
11 Bavarian Center for Cancer Research, Munich, Germany, Department of Radiation Oncology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany
12 Division of Transfusion Medicine, Cell Therapeutics, and Haemostaseology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
13 Division of Transfusion Medicine, Cell Therapeutics, and Haemostaseology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany, German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany
14 Experimental Leukemia and Lymphoma Research, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München, Germany
15 Experimental Leukemia and Lymphoma Research, Department of Medicine III, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, München, Germany, German Cancer Research Center (DKFZ), Heidelberg, Germany, German Consortium for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany

Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease characterized by recurrent genetic alterations that affect key regulators of hematopoiesis. AML patients with t(6;9)(p23;q34) translocation, resulting in the DEK::NUP214 fusion gene, belong to a rare but clinically aggressive AML subtype, accounting for approximately 1% of AML cases and classified as adverse risk under current WHO and ELN guidelines.

We applied whole-genome (n=14) and transcriptome sequencing (n=6) to DEK::NUP214-positive AML patients to characterize co-occurring genetic alterations. Remission samples serving as germline controls were available for 7 patients. Besides the DEK::NUP214 fusion, 12 genes were recurrently mutated, most frequently NRAS (50%), FLT3 (43%), MGA (36%), and NFIX (29%). Of note, we identified recurrent truncating mutations in NFIX, encoding the Nuclear Factor I X transcription factor. All detected NFIX alterations clustered within a hotspot region around amino acid position P382 and resulted in loss of the C-terminal transactivation domain. Variant allele frequencies ranged from 2% to 40%. NFIX plays an important role in controlling hematopoietic cell fate decisions, stem cell maintenance, and survival under stress (Holmfeldt et al., 2013, Blood). Despite its known role in normal hematopoiesis, the contribution of NFIX to AML pathogenesis remains poorly understood. To investigate functional consequences of NFIX alterations, we generated frameshift (p.P382Rfs*19) and stop gain (p.P382*) mutant expression constructs. Competitive growth assays in K-562 cells followed lentiviral transduction with NFIX wild-type, the two truncating mutants, or empty vector (EV). Overexpression of NFIX wild-type led to a progressive depletion of EGFP-positive cells, consistent with growth suppression. In contrast, cells expressing truncating NFIX mutants failed to inhibit cell proliferation, indicating loss-of-function. Western blot analysis in HEK293T cells verified stable expression of wild-type NFIX and the two truncated variants.

Transcriptome analysis revealed reduced NFIX expression in NFIX-mutant patients compared to wild-type patients (p=0.026), consistent with nonsense-mediated mRNA decay. Overall survival analysis in the AMLCG2008 cohort revealed a significantly better outcome (p=0.047) for cytogenetically normal patients with high NFIX expression (n=41) compared to patients with low expression (n=28), consistent with a putative tumor suppressor function. Together, these findings suggest that truncating NFIX alterations represent recurrent cooperating events in DEK::NUP214-positive AML and point toward a role of NFIX beyond the DEK::NUP214 subgroup.

To our knowledge, recurrent NFIX alterations have not previously been reported in AML, despite two decades of consortial high throughput sequencing efforts in large patient cohorts. In the publicly available datasets TCGA-LAML and BeatAML (n=1,005), we found NFIX variants in 5 cases, predominantly truncating (n=4/5, 80%), with n=2 located near the identified hotspot (BeatAML: T385Rfs*40, TCGA: T388Sfs*12), however, we have not found any evidence for concurrent DEK::NUP214 fusions. In our cohort, NFIX truncating variants clustered within a defined genomic region and were associated with reduced gene expression, suggesting a non-random event with potential functional relevance in DEK::NUP214-positive AML.

Recent evidence from solid tumor models further supports a tumor-suppressor role for NFIX. In breast cancer cells, NFIX overexpression impaired proliferation and delayed G2/M progression through repression of CDK1 expression (Ma et al., 2025, Cell Death Discov). Notably, CDKN1A (p21), an inhibitor of cyclin-dependent kinases and key regulator of G1/S progression, is among only three annotated transcriptional targets of NFIX and showed a trend toward reduced expression in NFIX-mutant samples (p=0.083). These findings support the hypothesis that recurrent NFIX truncations in DEK::NUP214-positive AML may represent loss-of-function events that impair cell cycle control and contribute to leukemic fitness.

In summary, we identified NFIX as a novel recurrently mutated gene in DEK::NUP214-positive AML, with truncating variants clustering in a defined genomic region and being associated with reduced gene expression. Functional assays provide evidence supporting a tumor suppressor role for NFIX in regulating leukemic cell growth.

Lisa Latzko: No relevant conflicts of interest to declare.